Last reviewed · How we verify
SAM-531
At a glance
| Generic name | SAM-531 |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease (PHASE2)
- To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers (PHASE1)
- Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered (PHASE1)
- Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered (PHASE1)
- Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease (PHASE2)
- Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects (PHASE1)
- Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males (PHASE1)
- Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAM-531 CI brief — competitive landscape report
- SAM-531 updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI